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The plasminogen activators, tissue type and urokinase type 
(tPA and uPA, respectively) have been identified in human 
skin under normal conditions and in various inflammatory 
dermatoses, including psoriasis. By Northern blot analyses, 
mRNA for uPA, but not for tPA, has been previously identi-
fied in epidermal extracts from normal skin, whereas in pso-
riasis, mRNA for tPA is readily detected. To further charac-
terize uP A and tP A expression in psoriasis, the localization of 
uPA and tPA mRNAs was evaluated by in situ hybridization. 
Studies were conducted using lesional and nonlesional skin of 
patients with psoriasis as well as normal skin. Additionally, in 
situ zymography using casein gel overlays was utilized to 
assess enzymatic activity. In psoriatic lesional skin, both uPA 
and tPA mRNAs were demonstrated by in situ hybridization. 
T he plasminogen activator (P A) enzymes, urokinase type (uPA) and tissue type (tPA) are proteases that catalyze the conversion of plasminogen to plasmin (reviewed in [1 J) . Plasmin is a serine protease that can hydrolyze a broad variety of proteins including many 
components of the extracellular matrix. Plasmin can activate the 
complement cascade by cleavage of c1, and it can also activate other 
proteases, including metalloproteases, to their active forms. Hence, 
the process of plasminogen activation initiates a cascade of proteoly-
tic events that may modulate cellular activities entailing the interac-
tion of the cell with its extracellular matrix, including migration, 
growth, and differentiation. 
Normal human epidermis contains r.lasminogen-activating 
(PA) activity, which is primarily uPA [2 . Messenger RNA for 
uPA is detected by Northern analyses, whereas mRNA for tPA 
is not detectable [3J . A number of cutaneous disorders includ.ing 
psoriasis are characterized by elevated levels of epidermal P A ac-
tivity [2,4]' More recently, it has been shown that the increased 
activity reflects induction of tPA expression [4J. The studies re-
ported herein demonstrate, with in sitll hybridization and zymo-
graphy technologies, that the previously observed quantitative 
changes in P A activity and expression reflect dramatic differences 
in the distribution of these enzymes in psoriatic versus normal 
skin. 
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Message for tPA was observed throughout the epidermis 
with areas of accentuation in the superficial stratum spino-
sum. Message for uPA was more focal and was localized 
primarily in the basal layer. Zymography showed tPA activ-
ity was coordinately increased in psoriatic lesions. Unin-
volved skin of psoriatic patients was sim.ilar to that of normal 
skin with respect to expression of plasminogen activators. In 
normal epidermis, neither tPA nor uPA mRNA could be 
detected by in situ hybridization. Activity for uPA, but not 
tPA, was observed by zymography. These studies suggest 
that alterations in plasminogen activators expression may 
contribute to the pathogenesis of psoriasis. Key words: in situ 
hybridization/proteases/zymography. ] InlJest Dermatol 102: 
333-338,1994 
MATERIALS AND METHODS 
Tissue All specimens were collected in accordance with a ptOtocol 
approved by the Committee for PtOtection of Human Subjects at the Uni-
versity of Pennsylvania. Normal skin, obtained from dermatologic sur-
gery, was from various sites including face, breast, and abdomen. Samples 
for ill silll hybridization were fixed in 4% paraformaldehyde in 0.1 M so-
dium phosphate (pH 7.4), dehydrated in graded ethanols, and paraffin em-
bedded. Six-mictOn sections were applied to Superfrost Plus slides (Fisher 
Scientific, Pittsburgh, PA). Samples for zymography were immediately ftO-
zen in liquid nitrogen and then embedded in PolyFreeze (Polysciences, 
Warrington, PA). 
In Situ Hybridization Sections were deparaflinized in xylenes, rehy-
drated in 50% ethanol in phosphate-buffered saline (PBS), and then fixed in 
4% paraformaldehyde in 0.1 M sodium phosphate (pH 7.4) for 10 min at 
4°C. Sections were washed in 0.5 X sodium citrate/sodium chloride buffer 
(SSe) (1 X SSC; 0.015 M sodium citrate, 0.15 M sodium chloride), incu-
bated with 10 ,ug/ml proteinase K (Boehringer Mannheim, Indianapolis, 
IN) in 10 mM Tris-HCI (pH 8) containing 0.5 M sodium chloride for 10 
min at room temperature and washed in 0.5 X SSe. The sections were 
prehybridized for 1 h at 55 °C and hybridized overnight at 58 °C in a mix-
ture of 50% formamide, 0.3 M sodium chloride, 20 mM Tris-HCI (pH 8), 
5 mM ethylenediamine tetraacetic acid (EDTA), 1 X Denhardt's solution 
(1 X Denhardt's solution; 0.02% bovine serum albumin. 0.02% Ficoll, 
0.020/0 polyvinylpyrolidone), 10% dextran sulfate, 10 mM dithiothreitol 
(OTT), and 500,ug/ml transfer RNA. Hybridizations were conducted using 
heat-denatured, 35S-labeled cRNA probes (6 X 106 cpm/ml). Non-specifi-
cally bound probe was removed by digestion with RNase A (20,ug/ml) in 
10 mM Tris-HCI (pH 8) containing 0.5 M sodium chloride for 45 min at 
room temperature. Sections were washed at high stringency in 0.1 X SSC 
containing 1 mM EDTA and 10 mM 2-mercaptoethanol for 2 h at 68°e. 
The sections were dehydrated and exposed to K.2 autoradiographic emul-
sion (Polysciences, Warrington, PA) for 2 weeks. After development, they 
were stained with hematoxylin and eosin. Sections were examined and 
photographed using epipolarization microscopy. 
cRNA Probes A 610-base pair (bp) fragment (positions 1364-1973) of 
the human uPA cDNA (pHUK-8) subcloned in pSP64 and pSP65 was the 
template for synthesis of antisense and sense uP A cRN A probes. respectively 
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
333 
334 SPLERS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Figure 1. III situ hybridization for cPA mRNA. III situ hybridization was 
conducted using an antisense cRNA probe for tPA in psoriatic lesional skin 
(A - D) as well as uninvolved skin (E) . Signal present in (E) is non-specific 
binding to the stratum corneum. A,C) hematoxylin and eosin. B,D,E) epi-
polarization. 
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[5] . A 614-bp fragme nt (positions 188 - 810) of the human tPA cD NA 
(p W349F) subcloned into pSP65 and pSP64 provided template for antisense 
and sense tPA cRNA probes. respectively [6]. RNA probes were generated by 
ill vitro transcription in the presence of35S-UTP (1000 Ci/mmole. Amer-
sham). Unincorporated radiolabel was removed from the probes by column 
purification. The specificity of the antisense uPA and tPA cRNA probes was 
verified by Northern analysis of total RNA prepared from human epidermis 
(normal and psoriatic) and keratinocyte cultures [4]. 
Zymogcaphy Zymo~raphy on cryostat tissue sections were conducted 
as described previously [7]; the overlay mixture consisted of 200,ul of PBS. 
133 ,ul of a 2.5% agar solution in water. and 20,ul of a 0.9 mgjml solu-
tion of purified human plasminogen. 67 ,Ill of an 8% Carnation instant 
nonfat dry milk solution in PBS and 1.2 ,ul of 10% sodium azide. This 
overlay mixture was prepared at 50 "C and 100,ul were applied to pre-
warmed 10-mm-thick cryostat sections mounted on Superfrost slides and 
spread evenly under 24 X 50 - mm glass coverslips. Slides were incu-
bated at 37 "C in humid chambers. and the development of zymograms was 
assessed after 6. 24. and 48 h. Identical experiments were carried out with 
overlay mixtures from which plasminogen was omitted to determine 
w hether the proteolysis was plasmin dependent. Inhibition studies were 
conducted to define the type of plasminogen activator present. For these 
studies. caseinolysis was evaluated using overlay mixtures containing plas-
minogen as well as 1 mM amiloride (an inhibitor of uPA, but not tPA or 
p lasmin) [8]. nonimmune immunoglobulin (Ig)G. rabbit anti-uPA IgG 
(final concentrations of25 . 50, or 100 ,ugjml), and goat anti-tPA IgG (final 
concentrations of 25, 50, or 100 ,ugjml). Blocking antibody to human 
urinary uPA was prepared as previously described [9]; antibody to tPA was 
purchased (product 387, American Diagnostica, Greenwich, CT). The 
specificity of the blocking activity of the antibodies for uPA and tPA was 
verified using the thiol ester substrate assay for plasmin activity described by 
Coleman and Green [10]' Caseinolysis was visualized as dark zones using 
dark field microscopy. 
Zymography performed in the presence of plasminogen showed a well-
demarcated zone of lysis throughout the epidermis of normal and psoriatic 
skin. Caseinolysis occurred in a time-dependent manner. The optimal incu-
bation period was 24 h, at which time the results were interpreted and 
photographed. Total clearing was evidenced by 48 h for both psoriatic and 
normal skins. No caseinolysis was observed when the overlay gels were 
prepared without plasminogen. Because of irregularities and artifacts of 
sectioning (clefts berween collagen bundles, folds in the tissue, knifemarks, 
etc.), the localization and types of PA activity within the dermis could not be 
interpreted by ill situ zymography. 
RESULTS 
In Situ Hybridization Expression of uPA and tPA message in 
normal skin and in biopsies of involved and uninvolved skin 
from patients with psoriasis was evaluated by hI sittl hybridization. 
In the psoriatic epidermis, message for both uPA and tPA was evi-
dent. The induction of tPA expression was present throughout 
·the epidermis. Areas of accentuation in the mid to upper stratum 
spinosum were identified (Fig 1). Lower levels of tPA mRNA 
were present throughout the rete ridges. Message for uPA was 
more restricted in distribution, being present primarily in the 
lower epidermis, particularly in the basal layer (Fig 2). N ei ther uPA 
nor tPA mRNA could be detected in uninvolved epidermis from 
psoriatic patients (Figs 1 and 2) or in normal epidermis (data not 
shown) . 
The specificity of the hybridization conditions was verified by 
the absence of signal above background levels in all specimens when 
radio labeled sense probes replaced the antisense probes. 
Data for psoriatic skin are representative of six involved plaques 
from three patients, two of whom also donated uninvolved skin for 
analyses. Each sample was hybridized in three independent experi-
ments. Alliesional skin samples showed similar results. Normal skin 
was obtained from 10 donors and was analyzed in three independent 
experiments and in no case could specific signal for uPA or tPA be 
identified. 
In Situ Zymography In situ zymography studies were conducted 
to assess whether the focal increases in PA mRNA expression 
w ithin the psoriatic epidermis were reflected in a coordinate en-
hancement of PA enzymatic activity. In zymography of psoriatic 
skin, caseinolysis was present throughout the full thickness of the 
epidermis, with the exception of the basal epithelial cells in sections 
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Figure 2. III situ hybridiza tion for uPA mRNA. III situ hybridization was 
conducted using an antisense cRNA probe for uPA in psoriatic lesional skin 
(A,B) as well as uninvolved skill (C) . A) hematoxylin and eosin. B,C) 
epipolarization. 
incubated for 24 h (Fig 3). This proteolysis was completely inhib-
ited in gels prepared with anti-tPA IgG (25, 50, 100 ,ug/ml), but was 
not inhibited by inclusion of anti-uPA IgG or normal goat IgG (25, 
50,100 ,ug/ml). Identical results were obtained from lesional skin of 
three patients with psoriasis in three independent experiments. 
These data demonstrate that the PA activity detected in psoriatic 
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Figure 3. Characterization of PA activity in psoriatic versus normal epidermis. III silll zymography was performed using cryostat sections of psoriatic and 
normal epidermis. In ~soriatic epidermis, no caseinolysis :wa~ observed in plas~!nogen-free gels (AJ, whereas clearing w~s see~ in gels containing plasminogen 
(B). Neutrahzmg antHPA IgG (50 ,u~/ml) completely 1Illub.lted casemolysis ~n the pr~sence of plasmmogen (C). No 1I1111bltlon occurred with normal goat 
IgG (100,ug/ml) (D). In normal epidermis, no casemolysis was observ~d m pl~snllnog.en-free gels (E), whereas cleanng was seen in gels containing 
plasminogen (F) . Neutrahzmg antl-uPA IgG (25 ,ug/ml) completely millbited casemolysis m the presence of plasmmogen (GJ. No inhibition occurred with 
normal rabbit IgG (25 JLg/ml) (H) . A-H) dark field microscopy. 
epidermis is predominantly tPA. This finding agrees with the re-
sults of zymographic analyses of extracts prepared from psoriatic 
epidermis [2,3]. Additionally, these studies localize PA activity to 
the suprabasal layers of the psoriatic lesion. 
For normal epidermis, the caseinolysis was apparent throughout 
the epidermis, sparing only the stratum corneum. Clearing was 
most pronounced over the basal layer. Proteolysis was completely 
inhibited with the inclusion of anti-uPA IgG (25, 50, 100,ugjml). 
No inhibition of caseinolysis was observed in the presence of anti-
tPA IgG (25, 50, 100,ugjml) or normal rabbit IgG (100,ugjml). No 
caseinolysis was detected with gels containing amiloride (1 mM), a 
specific inhibitor of uPA but not tPA (data not shown) [8]. For 
normal epidermis, identical results were obtained from two patients 
in three experiments. These data confirm that the PA activity in 
normal epidermis is predominantly uPA [2]. Finally, the localiza-
tion of PA activity to the basal area of the normal epidermis is 
notabl y different from that of psoriatic tissues. 
DISCUSSION 
Previously, the modulation of PA enzymatic activities and mRNA 
expression in psoriatic epidermis were quantitatively assessed using 
zymographic analyses of e£idermal extracts and Northern hybrid-
ization, respectively [2-4J . Additionally, immunohistochemical 
studies have demonstrated that psoriatic lesions stained focally for 
uPA in the basal epidermal cells of the supra papillary plates, whereas 
tPA was localized to the mid to upper stratum spinosum [11]. 
Neither uPA nor tPA is detected in normal epidermis by im-
munocytochemistry [11]. Nonetheless, biochemical analyses of 
epidermal extracts rrovide evidence for the presence of both uP A 
and tPA activity [2 . Thus, the enzymatic assays are tremendously 
more sensitive than immunocytochemical techniques for their de-
tection. 
The studies reported herein confirm and extend these observa-
tions. With ill situ hybridization, we show the localization of 
mRNAs for uPA and tPA in psoriatic lesions. The transcript for tPA 
was broadly distributed throughout all layers of the epidermis, with 
more pronounced areas in the uppermost portions. The message for 
uPA was focal and primarily present in the basal layer. Thus, the 
localization of uPA and tPA mRNAs within the psoriatic epidermis 
is largely in agreement with the previously reported distribution of 
uPA and tPA antigens [11]. 
The inability to detect uPA transcript in normal epidermis by 
ill situ hybridization, although uPA mRNA is apparent in normal 
epidermis using Northern analyses, suggests that uP A mRNA 
is expressed at I.ow levels and is not concentrated in a sub-popu-
lation of the epidermal cells. Messages of low expression may be 
difficult to detect by ill situ hybridization consequent to back-
ground signal. Likewise, the inability to detect enhanced levels 
of uPA mRNA by Northern analyses of mRNA from psoriatic epi-
dermis likely reflects the discrete localization of the induction of 
uPA expression. Data from N orthern analyses reflect changes in 
mRNA levels for the total epidermal cell population, whereas, ill 
sitll hybridization shows changes inmRNA expression at the cellu-
lar level. 
. With t.h~ in situ zymogr~phy technique, we have exploited the 
hl~h sensltlVlty of e~zyma~lc analyses for detection of plasminogen 
activators . Our studies are 111 concordance with biochemical studies 
showing t!lat ~PA i~ the predominant PA in epidermal extracts of 
normal sk111. LI~ewlse, our ill si.tu zymography results for psoriatic 
leSIOns ~e conslsten~ ~Ith studIes showing that tPA activity is the 
predom111ant PA actiVIty detected in extracts prepared from psori-
atic~laques [2,3]. The i/1 situ zymography studies reported herein 
addItt<?nally demons~rate that the localization of PA enzymatic ac-
tIVIty IS altered wIth111 the psoriatic epidermis. 
Previous studies in which autohistographic fibrin film was used 
to measure PA activity ill situ also showed tPA activity in psoriatic 
plaques [12]. With this technique, it was shown that a reduction in 
tPA-mediated fibrinolytic activity occurred with disease clearing 
consequent to a diversity of systemic ana local treatments (beta-
methaso~e valerate, anthralin, PUVA, hydrocolloid dressing). The 
localtzatlon of tP A activity within the psoriatic epidermis was not 
apparent by this technique; however. Additionally, PA activity in 
normal epidermis was not detected, probably consequent to the low 
sensItivity of the autohistogram fibrin film technique for uPA activ-
ity [12] . 
The inability to detect uP A activity in the basal cell layer of the 
psoriatic epidermis where there is uPA message and antigen sug-
gests that the enzyme is in an inactive form, as one might expect if 
the uPA were bound to a plasminogen activator inhibitor (PAl). 
Keratinocytes in culture express PAI-l and PAI-2 as well as both 
uPA and tPA [13] . Additionally, exudation ofPAI-l from the serum 
may occur with the vasodilatation and inflammation characteristic 
of the psoriatic lesion. Thus, we hypothesize that the uP A present in 
the psoriatic epidermis is inactive consequent to complex formation 
with either of these inhibitor proteins. Studies to localize message, 
antigen, and activity for PAI-l and PAI-2 are in progress to explore 
this possibility. 
The characteristic histopathology of psoriasis includes acan-
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thosis, regular elongation of the rete ridges, hypogranulosis, and 
parakeratosis admixed with neutrophils. These changes are believed 
to arise consequent to incomplete differentiation of the keratino-
cytes of the superficial epidermis. The induction ofPA expression in 
the basal layer provides evidence for a phenotypic change in the 
keratinocytes at the initial stages of differentiation. In lIitro, charac-
teristic alterations in P A expression occur with keratinocyte differ-
entiation [13,14]. Using the skin equivalent model, expression of 
uP A is detected in the basal layer, whereas tP A is identified in 
suprabasallayers [14]. Thus, the studies reported herein in conjunc-
tion with irJ lIitro studies provide compelling evidence for stage-spe-
cific expression of PA enzymes. 
Proteases have been postulated to affect intercellular adhesion of 
keratinocytes in disorders characterized by spongiosis and spongi-
form pustules. Psoriatic lesional skin has been shown to have ele-
vated elastase activity, a serine protease originating from poly-
morphonuclear leukocytes [15]. Skin-derived antileukoproteases 
(SKALPs) are also present in psoriatic epidermis and may be asso-
ciated with modulation of the inflammatory process [16,17]. 
Human leukocyte elastase activity is not specific to psoriasis, how-
ever, as it has been noted in lesional skin of atopic dermatitis and 
contact dermatitis [15] . Whereas aberrant PA profiles have been 
noted in a variety of cutaneous disorders such as Hailey-Hailey 
disease, pemphigus vulgaris, and psoriasis, it is possible that site-spe-
cific alterations in cellular sources may be disease related and poten-
tially more specific. 
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